A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes Ágnes BenedictEmily R. HankoskyBrian D. Benneyworth Current Opinion 07 June 2022 Pages: 743 - 750
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review Michal WitkowskiSøren Ilsøe MorenoSunita Nair Systematic Review Open access 05 July 2022 Pages: 751 - 776
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective Keith W. PratzXinglei ChaiEsprit Ma Original Research Article Open access 13 June 2022 Pages: 777 - 790
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease Katya GalactionovaPaola SalariMatthias Schwenkglenks Original Research Article Open access 20 June 2022 Pages: 791 - 806
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia Rachel SongVarinder JeetBonny Parkinson Original Research Article Open access 27 June 2022 Pages: 807 - 821
The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance Simon van der PolDanielle E. M. C. JansenAntoinette D. I. van Asselt Original Research Article Open access 29 June 2022 Pages: 823 - 833
Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease Katya GalactionovaPaola SalariMatthias Schwenkglenks Correction Open access 07 July 2022 Pages: 835 - 835